Delivery Order HHSO100201300006I-75A50118F33004
Award Date
9/13/18
Potential Completion Date
3/12/24
Potential Value
$154M
Awardee
Amgen USA Inc.
Ultimate Awardee
Amgen Inc.
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Thousand Oaks, CA 91320, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $35,943,677.00 definitive cost-type contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen Inc., a for-profit manufacturer, on September 26, 2019. The contract is to advance the development of romiplostim for treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT), as well as a drug delivery device feasibility project, with a...
This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Macrogenics, Inc., a for-profit manufacturer, for research and development services related to advanced development. The contract has a ceiling value of $56,058,625.93 and was awarded on September 29, 2006, with an ultimate completion date of September 28, 2011. The contract is not set-aside for any...
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a $124,993,937.09 cost-sharing definitive contract to Ossium Health, Inc., a for-profit biotechnology company, to develop a bone marrow cryogenic banking capability to treat acute radiation syndrome in a mass casualty emergency. The contract has an ultimate completion date of July 31, 2029 and was not set aside for any specific business type. Ossium Health has received...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $97,293.24 fixed-price delivery order supports the supply of NEUPOGEN 480MCG 10X1.6 VIAL 7532585268C078 (C078) medical products. This award is not designated as a set-aside contract. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a...
This is a $100,361,311 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the non-profit research organization MRIGlobal, also known as Midwest Research Institute, for the development of "Biodosimetry High-Throughput Diagnostic Tests." The contract supports the creation of diagnostic tests to evaluate radiation exposure, which is a critical capability for public health emergency preparedness. As a prime contractor,...
This is a $2,500,000.00 firm fixed price delivery order contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to MedImmune LLC. The contract is for the production of a Coronavirus Genomics Manufacturing and Production (CGMP) influenza vaccine clinical lot under the Pandemic Influenza Preparedness and Response 2012-2016 contract vehicle. There is no set-aside designation for this award. The ultimate...
This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Platelet Biogenesis, Inc. The contract, valued at $4,998,785.00, requires the contractor to utilize its technology to differentiate human induced pluripotent stem cells into pre-megakaryocytes, which are then cryopreserved. The frozen pre-megakaryocytes will be thawed and further differentiated into mature megakaryocytes. This...
The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $103,103.00 firm fixed-price purchase order contract to Cellgenix USA, a division of Cellgenix GMBH, a for-profit manufacturer of goods. The contract, which had no set-aside designation, is for the provision of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, interleukin-4, and other cell therapy reagents to support federal cell and gene therapy research...
This federal contract award, valued at $1,934.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NEUPOGEN 480 MCG/1.6 ML VIAL 1.6ML, a pharmaceutical product, with a performance period extending through March 28, 2025. The contract is a Delivery Order, with a Firm Fixed Price pricing type. It is not designated as a set-aside contract. Amerisourcebergen...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $4,595.11 for the supply of NEUPOGEN 480 MCG/0.8 ML SYR 0.8ML. The contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense (DoD), for the delivery of this pharmaceutical product. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is the prime contractor, and the contract is a firm fixed-price delivery...